NO973933D0 - Vaskulær endotelvekstfaktor B - Google Patents

Vaskulær endotelvekstfaktor B

Info

Publication number
NO973933D0
NO973933D0 NO973933A NO973933A NO973933D0 NO 973933 D0 NO973933 D0 NO 973933D0 NO 973933 A NO973933 A NO 973933A NO 973933 A NO973933 A NO 973933A NO 973933 D0 NO973933 D0 NO 973933D0
Authority
NO
Norway
Prior art keywords
vascular endothelial
polypeptides
growth factor
endothelial growth
vegf
Prior art date
Application number
NO973933A
Other languages
English (en)
Other versions
NO973933L (no
Inventor
Ulf Eriksson
Birgitta Olofsson
Kari Alitalo
Katri Pajusola
Original Assignee
Ludwig Inst Cancer Res
Helsingfors University Licensi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410265&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973933(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/469,427 external-priority patent/US5607918A/en
Application filed by Ludwig Inst Cancer Res, Helsingfors University Licensi filed Critical Ludwig Inst Cancer Res
Publication of NO973933D0 publication Critical patent/NO973933D0/no
Publication of NO973933L publication Critical patent/NO973933L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO973933A 1995-03-01 1997-08-27 Vaskulær endotelvekstfaktor B NO973933L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39765195A 1995-03-01 1995-03-01
US08/469,427 US5607918A (en) 1995-03-01 1995-06-06 Vascular endothelial growth factor-B and DNA coding therefor
US08/569,063 US5928939A (en) 1995-03-01 1995-12-06 Vascular endothelial growth factor-b and dna coding therefor
PCT/US1996/002957 WO1996026736A1 (en) 1995-03-01 1996-03-01 Vascular endothelial growth factor-b

Publications (2)

Publication Number Publication Date
NO973933D0 true NO973933D0 (no) 1997-08-27
NO973933L NO973933L (no) 1997-09-01

Family

ID=27410265

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973933A NO973933L (no) 1995-03-01 1997-08-27 Vaskulær endotelvekstfaktor B

Country Status (15)

Country Link
US (5) US5928939A (no)
EP (1) EP0814827B1 (no)
JP (2) JP3275024B2 (no)
CN (1) CN1146440C (no)
AT (1) ATE245437T1 (no)
AU (1) AU741856B2 (no)
CA (1) CA2211687C (no)
DE (1) DE69629181T2 (no)
DK (1) DK0814827T3 (no)
ES (1) ES2202432T3 (no)
HK (1) HK1008485A1 (no)
NO (1) NO973933L (no)
NZ (1) NZ305091A (no)
PT (1) PT814827E (no)
WO (1) WO1996026736A1 (no)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
ATE309360T1 (de) * 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
CN1194090C (zh) * 1995-03-02 2005-03-23 阿穆拉德业务有限公司 一种新的生长因子和编码这种生长因子的基因序列
US7160991B1 (en) 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
WO1996039421A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
CA2230957A1 (en) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
WO1998007832A1 (en) 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor
JP2000516478A (ja) * 1996-12-20 2000-12-12 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ Ｖｅｇｆ−ｂ／受容体複合体およびその利用方法
ATE296117T1 (de) 1997-03-07 2005-06-15 Wistar Inst Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
NZ514872A (en) * 1997-04-25 2005-01-28 Collateral Therapeutics Truncated VEGF-B, VRF-2, VEGF-C, PlGF, VEGF-3, poxvirus ORF-1 and poxvirus ORF-2 proteins
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
ATE556090T1 (de) 1998-11-10 2012-05-15 Ludwig Inst Cancer Res Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
JP2002535006A (ja) * 1999-01-29 2002-10-22 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 血小板由来増殖因子／血管内皮増殖因子様増殖因子ｈとその利用法
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
JP2004513328A (ja) * 1999-03-03 2004-04-30 ルードヴィッヒ　インスティテュート　フォー　キャンサー　リサーチ 血管内皮増殖因子（ｖｅｇｆ−ｂ）欠損動物の心臓異常及びこれら心臓異常に関する方法
WO2000064261A1 (en) * 1999-04-26 2000-11-02 Ludwig Institute For Cancer Research Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
JP2003501092A (ja) * 1999-06-07 2003-01-14 エドワーズ ライフサイエンシーズ コーポレイション 標的化新脈管形成
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
EP1202736B1 (en) * 1999-07-28 2008-09-17 The Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
EP1255560B1 (en) * 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40 ligand adjuvant for respiratory syncytial virus vaccine
AUPQ568100A0 (en) * 2000-02-16 2000-03-09 Amrad Operations Pty. Limited A method for producing recombinant molecules
DE60131146T2 (de) * 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
NZ522014A (en) * 2000-05-17 2007-03-30 Ludwig Inst Cancer Res Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
KR20030074588A (ko) * 2000-07-26 2003-09-19 루드빅 인스티튜트 포 캔서 리서치 글리코실화 ｖｅｇｆ-ｂ 및 가용성 ｖｅｇｆ-ｂ 의 양을증가시키는 방법
NZ518077A (en) * 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
WO2002029087A2 (en) * 2000-10-02 2002-04-11 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
AU2002224471A1 (en) * 2000-11-01 2002-05-15 Aventis Pharma S.A. In vivo stimulation of angiogenic activity
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20070050857A1 (en) * 2001-02-28 2007-03-01 Hayward Nick K Method of treatment and prophylaxis
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
WO2002083704A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
US20050043227A1 (en) * 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
JP2005505510A (ja) * 2001-06-20 2005-02-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｖｅｇｆ−ｂによる血管新生の刺激
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
JP2005500045A (ja) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
WO2003018752A2 (en) 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20040005671A1 (en) * 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
EP1912069A3 (en) 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
EP1514114A4 (en) * 2002-06-05 2007-03-21 Sopherion Therapeutics Inc PROCESS FOR SCREENING LIGANDS USING EUKARYONTIC CELL DISPLAY
US20030232439A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CA2493572A1 (en) 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
JP4672370B2 (ja) * 2002-12-05 2011-04-20 ケース ウエスタン リザーブ ユニバーシティ 虚血の細胞ベースの治療
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
DK1660057T3 (da) 2003-08-27 2012-08-20 Ophthotech Corp Kombinationsterapi til behandling af neovaskulære øjenlidelser
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
WO2005084329A2 (en) * 2004-03-02 2005-09-15 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
WO2005099771A2 (en) * 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
DK2476427T3 (en) * 2004-08-02 2018-05-07 Zenyth Operations Pty Ltd METHOD OF TREATING CANCER INCLUDING A VEGF-B ANTAGONIST
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
JP4988606B2 (ja) * 2005-02-28 2012-08-01 サンガモ バイオサイエンシズ インコーポレイテッド 抗血管新生方法及び組成物
BRPI0610499A2 (pt) * 2005-04-12 2010-06-22 Intradigm Corp moléculas de ácido nucléico , composições e usos das referidas moléculas
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
BRPI0619225A2 (pt) * 2005-12-01 2017-11-07 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
US8114399B2 (en) 2006-05-17 2012-02-14 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
UA102993C2 (ru) * 2007-06-06 2013-09-10 Домантис Лимитед Анти-vegf единичный вариабельный домен иммуноглобулина
US7819579B2 (en) * 2007-11-26 2010-10-26 Schmulenson Harold K Radiation sensing device and holder
WO2009075565A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
US8637026B2 (en) 2007-12-26 2014-01-28 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
EP2271365A4 (en) * 2008-04-09 2011-10-26 Ludwig Inst Cancer Res REGULATION OF FATTY ACID TRANSPORTERS
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
RU2477529C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
KR20160030396A (ko) 2013-07-12 2016-03-17 옵쏘테크 코포레이션 안과적 질환을 치료하거나 예방하기 위한 방법
JP6553618B2 (ja) * 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
US10745454B2 (en) * 2018-01-31 2020-08-18 Seyed Mohsen Asghari Method of synthesizing antagonist peptides for cell growth
CN109337931A (zh) * 2018-11-02 2019-02-15 东北师范大学 Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
CN110777146A (zh) * 2019-11-28 2020-02-11 南通大学 一种pdgfb启动子活性报告质粒的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
ATE309360T1 (de) * 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
CN1194090C (zh) * 1995-03-02 2005-03-23 阿穆拉德业务有限公司 一种新的生长因子和编码这种生长因子的基因序列
WO1996039421A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3

Also Published As

Publication number Publication date
JP3297687B2 (ja) 2002-07-02
JP3275024B2 (ja) 2002-04-15
US7341996B2 (en) 2008-03-11
EP0814827B1 (en) 2003-07-23
AU5302196A (en) 1996-09-18
ES2202432T3 (es) 2004-04-01
US5928939A (en) 1999-07-27
EP0814827A4 (en) 1999-11-10
HK1008485A1 (en) 1999-07-30
US20050064493A1 (en) 2005-03-24
DK0814827T3 (da) 2003-11-10
US6331301B1 (en) 2001-12-18
WO1996026736A1 (en) 1996-09-06
EP0814827A1 (en) 1998-01-07
AU741856B2 (en) 2001-12-13
JP2000228982A (ja) 2000-08-22
DE69629181T2 (de) 2004-05-13
PT814827E (pt) 2003-11-28
CN1176603A (zh) 1998-03-18
CA2211687A1 (en) 1996-09-06
US20030170253A1 (en) 2003-09-11
JPH10510718A (ja) 1998-10-20
ATE245437T1 (de) 2003-08-15
CN1146440C (zh) 2004-04-21
NZ305091A (en) 1998-11-25
CA2211687C (en) 2011-05-24
NO973933L (no) 1997-09-01
US5840693A (en) 1998-11-24
DE69629181D1 (de) 2003-08-28

Similar Documents

Publication Publication Date Title
NO973933D0 (no) Vaskulær endotelvekstfaktor B
DK1749836T3 (da) Rekombinant vaskulær endothelcellevækstfaktor D
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
ATE391778T1 (de) Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
ATE544776T1 (de) Chimäre dna-bindeproteine
AU2002305450A1 (en) Proteomimetic compounds and methods
DE69941791D1 (de) Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
EP2301563A3 (en) HSP20 peptides
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
ATE182628T1 (de) Ein protein, das spezifische dna-strukturen erkennt, und seine verwendungen
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ES2191033T3 (es) Alergenos recombinantes de cladosporium herbarum.
WO2001025437A3 (en) Growth factor polypeptides and nucleic acids encoding same
ATE332923T1 (de) Cr1 fragmente und deren verwendung